Belgium medtech startup Hippo DX raises €4.4M for its fast, cheap and accurate allergy testing device

Hippo DX is a MedTech start-up introducing a state-of-the-art medical device, S.P.A.T. (Skin Prick Automated Test) for automated allergy testing. The S.P.A.T. device executes 12 equal pricks simultaneously in 20 seconds. It images the pricked spots 15 minutes after pricking, offering standardised and digital results for seamless record-keeping. Here are details of Hippo DX‘s latest funding round :

🚀 Launch

2020

🏭 Industry

Medical equipment

🧠Management

Senne Gorris (CEO – Founder), Dirk Loeckx (CTO), Sven Seys (CSO), Sara Shafaq (Chief Business Officer), Bert Vrancx (COO)

💸 Funding & Investors

INVESTMENT (October 2023)€4.4 million
INVESTORS (October 2023)Among others, LRM and the American Allerfund Ventures

🎯 Funding purpose

Operations expansion

🌐 Country HQ

Belgium (Aarschot)

Leave a Reply

Your email address will not be published.